Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IM Cannabis Corp C.IMCC

Alternate Symbol(s):  IMCC

IM Cannabis Corp. is a Canada-based international cannabis company that provides cannabis products to medical patients in Israel and Germany. The Company's ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel. In Germany, the Company operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. It offers four different product lines, leading with the Craft Collection which offers the highest quality Canadian craft cannabis flower. The Company's other product lines include Top-Shelf Collection, Signature Collection and Full Spectrum Extracts. The Company's brands include The WAGNERS, BLKMKT, LOT420, and The PICO collection (minis).


CSE:IMCC - Post by User

Post by RockMaschineon Apr 23, 2021 9:37am
180 Views
Post# 33054301

Excellent projected revenue growth

Excellent projected revenue growth
5 mill in Q4, $15 million for fiscal 2020 and excellent growth projected for the rest of the year including profitability. Add in MYM and Trichome numbers and run rate exiting the year to exceed $80-100 million if all goes well.
<< Previous
Bullboard Posts
Next >>